Sponsored / 9 Min Read

Erasing Addiction from

the Brain?

Awakn Life Sciences is a cutting-edge psych-e-delics biotech displaying profit potential in a matter of months; not years…

Awakn Life Sciences’ 5 Crucial Advantages in the Growing Field of Psych-e-delic Therapy:

Awakn Life Sciences is a pioneering biotechnology firm that’s uniquely positioned to capitalize on the UK’s growing market for psych-e-delic therapeutics, just as the country’s Prime Minister is considering the legalization of dr-ugs like psi-lo-cybin. (Source 23)

Led by Dr. Ben Sessa, one of the most popular trailblazers in the space, Awakn Life Sciences’ is building a growing network of psych-e-delic treatment clinics starting in the UK (in both London and Bristol), that’s projected to deliver $109 million in new revenue by 2024. (Source 2)

In addition to its “on-the-ground” presence, the company is developing a strong portfolio of proprietary research, including the world’s only MD-MA-assisted Psychotherapy and AUD study (BIMA), as well as the world’s only study on Ket-a-mine-Assisted Psychotherapy AUD (KARE). (Source 15)

The company’s growing revenue stream from current and future clinics is largely reinvested back into research and development, with a pipeline of commercial products planned through 2028. (Source 2)

With the broader market for psych-e-delics poised to soar to $100 Billion in the near future (Source 19), Awakn Life Sciences is uniquely focused on building a strong customer-facing brand with massive licensing opportunities and the potential for runaway revenues.

January 11, 2022

Awakn Life Sciences Announces Positive Results from Phase II A/B Ketamine-Assisted Therapy for Treatment of Alcohol Use Disorder Trial

Psych-e-delic Therapeutics is one of the fastest growing and most fascinating markets on everyone’s mind …

Just a few years ago, the idea wasn’t taken seriously… 

Now even the UK’s Conservative politicians are urging their prime minister to consider legalizing Psi-lo-cybin, the core ingredient in “

Magic Mush-rooms(23)

Even after finding popularity as a rave dr-ug with the street name of “Ecs-tasy,” MD-MA research continues to show powerful results in treating those with PTSD. (11) (20) The result is nothing short of an “overnight” success. 

We are now looking at a market segment that didn’t even exist just over a year ago, which is widely reported to be on its way to $100 Billion in annual business. (19)

This revolutionary new therapy could be a miracle that offers truly transformative results for addicts and those who struggle with mental health. And Awakn Life Sciences has the potential to haul in the kinds of profits that may only come around once in a century.

Awakn Life Sciences Could Soon Be a Household Name…Here’s Why

There are dozens of psych-e-delic pharmaceutical companies to research. So what makes Awakn Life Sciences different?

Simple. They are ACTUALLY delivering psych-e-delic therapeutics (medicines and therapies) to treat addiction…right now…today. 

The fact is none of these other “hot” psych-e-delics firms have approved therapies on the market or have reached profitability yet.

In October 2021, Awakn Clinics Bristol received Care Quality Commission’s (CQC) formal approval to begin treatments. 

What’s so impressive is that this was the second of three Awakn clinics to be operational this year: Bristol and London in the U.K. and Oslo in Norway which was the first. 

Treatments at the clinic will be led by on-site psychiatrists and will treat a number of mental health disorders and addictions. (24)

And what does all this add up to? Current and future potential revenues.

Awakn Life Sciences: An Effective New Answer for the Global Mental Health Crisis

We’ve seen massive advancements in practical medicine over recent years, from mRNA vaccines to sophisticated new diagnostic gear. But in terms of addressing mental health, most methods are woefully outdated …

Americans, just like folks from all over, are struggling to cope with a rapidly-changing world. And unfortunately for them, psychiatry doesn’t yet have an easy answer or even an effective cure for common mental health issues.

Instead, doctors advise their patients to focus on suppressing the symptoms without ever really addressing the root cure of their frustratingly recurrent illness. Without a more effective tool at their disposal, doctors have prescribed anti-depressants in increasingly massive amounts. According to the CDC, anti-depressant usage has skyrocketed by 400% between 1988 and 2008 (Source 8).

Even worse, many turn to illicit substances in order to self-medicate and meet their own needs. Make no mistake—the Global Mental Health Crisis is in many ways an Addiction Crisis.

 

Fully 1.3 billion people struggle with some form of addiction (Source 2). That’s roughly one in three adults worldwide. Of those, 390 million struggle with alcoholism, and 39 million more with extremely dangerous opioids (see the chart below). 

Many of these people would eagerly embrace any solution to free themselves from the dangerous cycle of addiction. But as we all know, modern treatments simply aren’t working. It’s estimated that 16% of alcohol abusers will seek some form of medical treatment. Of those who do, fully 75% have been shown to relapse within 12 months (Source 9).

Outdated solutions simply aren’t working anymore. But early research shows that some psych-e-delics could be a more effective solution to common mental health & addiction issues …

Awakn Life Sciences: Erasing Addiction from the Brain?

These alternative therapies, when used correctly and in a medical setting, can effectively help to erase addiction from the brain, breaking the cycle of dangerous habits by accounting for (and helping to adjust) the complex brain function that drives them.

The science behind these new therapies is complicated, but the results so far have been outstanding. In a 2019 study from the Journal for Psychoactive Dr-ugs, 235 different patients reported significant average decreases in depression and anxiety while taking prescribed doses of Ket-a-mine (Source 21).

Another study from Johns Hopkins focused on a small group of adults suffering from major clinical depression (Source 22).

Their conclusion:

The magnitude of the effect we saw [from Ket-a-mine] was about four times larger than what clinical trials have shown for traditional antidepressants on the market,” Alan Davis, Ph. D. (22)

With practically unrivaled potential for growth in coming years. It’s estimated the industry could soon soar to $100 Billion in size with targeted treatment markets worth over $330 Billion in total:

Investors are just beginning to tune in—with the sector’s first runaway stock MindMed soaring 240.91% (Source 3) over the last year. Psych-e-delics stocks are increasingly making headlines, especially as revenues start to materialize. The sector even got its first actively-managed ETF in 2021 (Source 14).

Yet even as this brand-new sector explodes with opportunity, it’s still filled with complex, sophisticated challenges in terms of everything from regulation to finance. These challenges are ever-evolving, and they’re different for almost every country out there. In order to succeed on a truly global scale, it will take more than just innovation …

 

Awakn Life Sciences: (OTCQB:AWKNF) (NEO:AWKN): A Winning Strategy for a Complex New Market

 

Among the new crop of biotech stocks in this sector, none quite match up with Awakn Life Sciences …
The company’s co-founder, Dr. Ben Sessa, is famous in this relatively small community for leading the world’s only MD-MA-assisted Psychotherapy and AUD study (BIMA), as well as the world’s only study on Ket-a-mine-Assisted Psychotherapy AUD (KARE) (Source 15).

Dr. Sessa’s presence on the team alone gives Awakn Life Sciences a massive head-start in what may soon be an extremely competitive space, but that’s just the beginning …

Awakn Life Sciences also has 10 different patent filings covering multiple chemical series, and 6 years of proprietary research data acquired from Professor David Nutt’s research company Equasy (Source 9).

Instead of overspecializing like most of the competition, the company is developing a vertically-integrated pipeline to develop and distribute their own proprietary treatments. That means they’re doing everything in-house, from the development of new compounds to the application of therapy and treatment:

This vertical integration is important because it means Awakn will be controlling the whole ecosystem through every step of the process. This provides an unrivaled level of quality control and fidelity, especially when many other firms are outsourcing various parts of the process.

Remember; we’re talking about an entirely new medical field here. Nothing is written for stone for any of these companies. So by controlling every step of the process—from research to end-user— Awakn Life Sciences can patent their treatment processes 

Based on Dr. Sessa’s advanced research, Awakn Life Sciences will be focusing on the use of Ketamine to treat substance addiction and behavioral disorders, with MDMA reserved for the treatment of alcohol abuse. These treatments will be distributed through a network of clinics, largely targeting the UK and Europe in the near-term. The company projects a network of 20 clinics by the end of 2024, with a total forecast of $109 million (2).

As their portfolio expands and the brand strengthens, Awakn Life Sciences projects developing licensing partnerships by 2022, with the potential for commercialization of therapeutics as early as 2025 (Source 2).

Awakn Life Sciences has some extremely compelling plans for the future; and the company is uniquely positioned to make them come true. But how does it all look on paper right now?

 

Awakn Life Sciences Defying Expectations and Easy Assessment

Awakn Life Sciences is a pure ground-floor play with a limited track record and promising fundamentals.
Shares first listed on the NEO on June 23, 2021, and on the OTC just a few weeks later on August 3, 2021. That means you’re limited to a few weeks of chart space on both indices, which just isn’t a large enough sample.

Where the company really shines is in the fine print. Awakn Life Sciences has $49 million in market capitalization and, as of writing, the company is debt-free (very impressive). They’ve just acquired a leading Ket-a-mine-assisted Psychotherapy Clinic in Norway, which will likely soon be delivering on reportable revenue (Source 6). In the longer term, they’ve recently acquired exclusive rights to a treasure trove of MD-MA research in the UK, which will help to further refine their core offerings (Source 16).

Awakn Life Sciences employs just 18 people and is based in Vancouver, British Columbia. Among those employees is CEO Anthony Tennyson, whose compensation is just $51,828 CAD. That’s over $100,000 CAD less than comparable CEOs at similarly-sized companies (Source 4). Curiously, it’s almost the exact amount that the average Canadian makes (almost certainly a deliberate decision) (Source 18).

It’s even more remarkable when you consider the outstanding rate of insider buying. Tennyson himself made a $43,259 CAD purchase on August 15th (Source 4). Between himself and the 17 other employees of the company, insiders are reported to own a full 11.59% of all outstanding shares (Source 17).

This is a notable amount of insider buying to see in any company. Doubly so when you consider a management team that isn’t greedy about their base pay.
It’s quite possible the team at Awakn Life Sciences knows something about their products or their pipeline that we don’t …

Awakn Life Sciences Multinational Experts & Leading Medical Minds

We’ve already mentioned Dr. Ben Sessa and Anthony Tennyson, both co-founders of Awakn Life Sciences.

It’s worth noting that Tennyson’s background is equally impressive as his partner’s, with 10 years of executive experience in developing international strategies, as well as 5 more years working with Merrill Lynch and Bank of Ireland (Source 15). This means the team should have an added advantage when it comes to credit access and financial stability.

The company’s Chair, George Scorsis, is a specialist in leading companies through highly-regulated markets, a key asset when it comes to the company’s international growth. Scorsis was formerly President of Red Bull Canada (Source 15).

Beyond this core team, the company additionally works with a handful of Independent directors like Steve Page, whose 30 years’ experience in UK healthcare is indispensable to the team’s new London operation, and Professor John Papastergiou, who helps to lead the team’s focused research efforts.

Working together, this relatively small team is poised to start delivering results all over Europe and the UK.

 

Awakn Life Sciences (OTCQB:AWKNF) (NEO:AWKN) Making Headlines is Just the Beginning …

 

Awakn Life Sciences and founder Dr. Ben Sessa have already been featured in a wide variety of publications, and will no doubt continue to make headlines as a leader in the groundbreaking new space of alternative therapy, MD-MA and Ket-a-mine therapy.

 

Uniting some of the sharpest leaders in Biotech with a clear vision for improving treatment, Awakn Life Sciences is poised to transform this new marketplace and deliver unrivaled results.

Awakn Life Sciences’ 5 Crucial Advantages in the 
Growing Field of Psychedelic Therapy:

Asset-49-01

Awakn Life Sciences is a pioneering biotechnology firm that’s uniquely positioned to capitalize on the UK’s growing market for psych-e-delic therapeutics, just as the country’s Prime Minister is considering the legalization of dr-ugs like psi-lo-cybin. (Source 23)

Asset-49-01

Led by Dr. Ben Sessa, one of the most popular trailblazers in the space, Awakn Life Sciences’ is building a growing network of psych-e-delic treatment clinics starting in the UK (in both London and Bristol), that’s projected to deliver $109 million in new revenue by 2024. (Source 2)

Asset-49-01

In addition to its “on-the-ground” presence, the company is developing a strong portfolio of proprietary research, including the world’s only MD-MA-assisted Psychotherapy and AUD study (BIMA), as well as the world’s only study on Ket-a-mine-Assisted Psychotherapy AUD (KARE). (Source 15)

Asset-49-01

The company’s growing revenue stream from current and future clinics is largely reinvested back into research and development, with a pipeline of commercial products planned through 2028. (Source 2)

Asset-49-01

With the broader market for psych-e-delics poised to soar to $100 Billion in the near future (Source 19), Awakn Life Sciences is uniquely focused on building a strong customer-facing brand with massive licensing opportunities and the potential for runaway revenues.

Source 1: https://secureservercdn.net/45.40.148.147/3kn.ae3.myftpupload.com/wp-content/uploads/2021/07/fact-sheet-jul21.pdf

Source 2: https://english.cambodiadaily.com/news/scraping-out-a-living-in-pailins-spent-gem-mines-61043/

Source 4: https://investingnews.com/company-profiles/angkor-resources-tsxv-ank-copper-molybdenum-cambodia/

Source 5: https://resourceworld.com/angkor-resources-reports-multiple-high-grade-cambodia-samples/

Source 6: https://investingnews.com/company-profiles/angkor-resources-tsxv-ank-copper-molybdenum-cambodia/

Source 7: https://www.juniorminingnetwork.com/junior-miner-news/press-releases/636-tsx-venture/ank/34265-angkor-gold-signs-definitive-earn-in-agreement-with-renaissance-minerals-for-koan-nheak-property-cambodia.html

Source 8: https://www.phnompenhpost.com/business/renaissance-minerals-says-it-will-extract-gold-next-year

Source 9: https://investorintel.com/investorintel-video/angkor-gold-gold-standard-social-responsibility/

Source 10: https://angkorresources.ca/projects/

Source 11: https://www.khmertimeskh.com/50833315/angkor-resources-set-to-tap-well-of-gold-in-ratanakiri/

Source 12: https://www.bnnbloomberg.ca/angkor-gold-corp-s-embarrassment-of-riches-includes-cambodian-well-of-gold-1.929092

Source 13: https://www.khmertimeskh.com/50836184/glittering-gold-prospects-says-mining-business/

Source 14: https://www.globenewswire.com/en/news-release/2020/08/26/2084055/0/en/Angkor-Reports-Additional-High-Grade-Samples-With-Up-to-70-7-g-t-Gold-From-Selected-Samples-From-Its-Andong-Meas-Property.html

Source 15: https://www.mining.com/the-worlds-highest-grade-gold-mines/

Source 16: https://investorintel.com/markets/gold-silver-base-metals/gold-precious-metals-intel/angkor-resources-is-looking-to-follow-in-emerald-resources-footsteps-of-gold-explorer-to-near-term-producer-in-cambodia/?print=print

Source 17: https://www.kitco.com/gold-price-today-usa/

Source 18: https://www.yahoo.com/now/angkor-resources-announces-139-metres-123000336.html

Source 19: https://investorintel.com/markets/gold-silver-base-metals/gold-precious-metals-intel/angkor-resources-is-looking-to-follow-in-emerald-resources-footsteps-of-gold-explorer-to-near-term-producer-in-cambodia/

Source 20: https://investorintel.com/markets/gold-silver-base-metals/gold-precious-metals-intel/angkor-resources-is-looking-to-follow-in-emerald-resources-footsteps-of-gold-explorer-to-near-term-producer-in-cambodia/

Source 21: https://simplywall.st/stocks/ca/materials/tsxv-ank/angkor-resources-shares#ownership_summary

Source 22: https://finance.yahoo.com/news/angkor-resources-signs-letter-intent-124500090.html

Source 23: https://www.nasdaq.com/articles/precious-gold-near-5-month-high-as-inflation-fears-deepen

GET RED-HOT STOCK TIPS DELIVERED DIRECT TO YOUR INBOX:

Disclaimer

Privacy Policy

Discover More.

Sign up for news on more investor relations.

Policy information place here.